Enriched clinical annotations |
For each of the clinical annotations, we tested whether it was enriched in the set of arrays in which the module is significantly induced (or repressed). Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of induced (or repressed) module's arrays in which they appear. We also show the fraction of the module's induced (or repressed) arrays with the given annotation ('Hits (%)' column). For completeness, we also list the total number of relevant induced arrays in the module ('Module hits in category' column), total number of arrays in the compendium in which the corresponding annotation is present ('Arrays in annotation' column), and the total number of relevant arrays in the compendium ('Arrays' column). Note that the 'relevant' arrays may be different for each annotation, since it includes only arrays in which the annotation was relevant (i.e., present or not present) and excludes arrays where the value of the annotation was not known. Rows that correspond to annotations that were enriched in the induced arrays of the module have a red background, while rows corresponding to annotations enriched in the repressed arrays have a green background. For each annotation, we also list the other modules in which it was enriched. |
Clinical annotation |
Category |
P-value |
Hits |
Hits(%) |
Module hits in category |
Arrays in annotation |
Arrays |
Liver tissue (Liver cancer*) |
Liver cancer* |
2.9e-60 |
91 |
57.9 |
157 |
187 |
1945 |
Liver tissue, cancer or cell line (Liver cancer*) |
Liver cancer* |
1.2e-57 |
91 |
57.9 |
157 |
197 |
1945 |
Hepatitis infected liver (Liver cancer*) |
Liver cancer* |
4.8e-41 |
70 |
44.5 |
157 |
156 |
1945 |
Liver tissue, cancer or cell line (Liver cancer*) |
Liver cancer* |
5.5e-21 |
54 |
38.2 |
141 |
197 |
1945 |
Non-tumor liver tissue (Liver cancer) |
Liver cancer |
9.7e-20 |
64 |
70.3 |
91 |
76 |
207 |
Cancer and cell line (Liver cancer) |
Liver cancer |
2.0e-16 |
63 |
98.4 |
64 |
126 |
207 |
Prostate (Prostate cancer*) |
Prostate cancer* |
4.8e-15 |
33 |
23.4 |
141 |
101 |
1945 |
Hepatitis infected liver (Liver cancer*) |
Liver cancer* |
3.9e-14 |
40 |
28.3 |
141 |
156 |
1945 |
Liver tissue (Liver cancer*) |
Liver cancer* |
4.4e-14 |
44 |
31.2 |
141 |
187 |
1945 |
Cancer (Liver cancer) |
Liver cancer |
5.8e-08 |
53 |
82.8 |
64 |
115 |
207 |
Liver cancer cell line (Liver cancer) |
Liver cancer |
4.7e-06 |
10 |
15.6 |
64 |
10 |
207 |
Metastasis (Liver cancer) |
Liver cancer |
4.7e-06 |
10 |
15.6 |
64 |
10 |
207 |
Adenocarcinoma (Liver cancer) |
Liver cancer |
5.2e-06 |
45 |
70.3 |
64 |
97 |
207 |
Cell line (Liver cancer) |
Liver cancer |
3.9e-05 |
10 |
15.6 |
64 |
11 |
207 |
Lung carcinoid (Lung cancer) |
Lung cancer |
4.6e-05 |
6 |
50 |
12 |
20 |
276 |
Hematologic cancer and cell line (Stimulated immune*) |
Stimulated immune* |
5.9e-05 |
13 |
9.2 |
141 |
53 |
1945 |
Hematologic samples and cell lines (Stimulated immune*) |
Stimulated immune* |
5.9e-05 |
13 |
9.2 |
141 |
53 |
1945 |
Macrophages (Stimulated immune*) |
Stimulated immune* |
5.9e-05 |
13 |
9.2 |
141 |
53 |
1945 |
Monocytes (Stimulated immune*) |
Stimulated immune* |
5.9e-05 |
13 |
9.2 |
141 |
53 |
1945 |
Normal tissue (Liver cancer) |
Liver cancer |
0.0001 |
13 |
14.2 |
91 |
14 |
207 |
Hematologic cancer and cell line (Stimulated immune*) |
Stimulated immune* |
0.0001 |
13 |
8.2 |
157 |
53 |
1945 |
Hematologic samples and cell lines (Stimulated immune*) |
Stimulated immune* |
0.0001 |
13 |
8.2 |
157 |
53 |
1945 |
Macrophages (Stimulated immune*) |
Stimulated immune* |
0.0001 |
13 |
8.2 |
157 |
53 |
1945 |
Monocytes (Stimulated immune*) |
Stimulated immune* |
0.0001 |
13 |
8.2 |
157 |
53 |
1945 |
Enriched GO annotations |
For each GO annotation, we tested whether it was enriched in the set of genes of the module. Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of the module's genes in which they appear. We also show the fraction of the module's genes with the given GO annotation that are included in this module ('Hits (%)' column). For completeness, we also list the total number of genes in the module ('Module genes' column), total number of genes in the compendium in which the corresponding annotation is present ('Genes in annotation' column), and the total number of genes in the compendium ('Genes' column). |
GO annotation |
P-value |
Hits |
Hits(%) |
Module genes |
Genes in annotation |
Genes |
energy pathways |
1.1e-131 |
94 |
94.9 |
99 |
200 |
4566 |
photosynthesis |
1.4e-95 |
75 |
75.7 |
99 |
162 |
4566 |
electron transport |
1.2e-81 |
64 |
64.6 |
99 |
128 |
4566 |
photosynthesis\, light reaction |
4.1e-73 |
58 |
58.5 |
99 |
115 |
4566 |
electron transporter activity |
3.2e-58 |
65 |
65.6 |
99 |
269 |
4566 |
oxidoreductase activity |
3.9e-52 |
60 |
60.6 |
99 |
254 |
4566 |
mitochondrion |
6.0e-28 |
39 |
39.3 |
99 |
207 |
4566 |
energy derivation by oxidation of organic compounds |
9.6e-24 |
22 |
22.2 |
99 |
54 |
4566 |
main pathways of carbohydrate metabolism |
8.4e-17 |
15 |
15.1 |
99 |
35 |
4566 |
mitochondrial membrane |
7.4e-15 |
16 |
16.1 |
99 |
54 |
4566 |
monovalent inorganic cation transporter activity |
2.7e-14 |
18 |
18.1 |
99 |
80 |
4566 |
oxidoreductase activity\, acting on paired donors\, with incorporation or reduction of molecular oxygen |
1.3e-13 |
14 |
14.1 |
99 |
44 |
4566 |
monooxygenase activity |
3.0e-13 |
11 |
11.1 |
99 |
23 |
4566 |
tricarboxylic acid cycle |
3.2e-12 |
9 |
9.0 |
99 |
15 |
4566 |
carbohydrate metabolism |
6.5e-12 |
19 |
19.1 |
99 |
123 |
4566 |
fatty acid metabolism |
7.1e-12 |
14 |
14.1 |
99 |
57 |
4566 |
oxidoreductase activity\, acting on the CH-CH group of donors |
1.5e-11 |
9 |
9.0 |
99 |
17 |
4566 |
ion transporter activity |
1.1e-10 |
19 |
19.1 |
99 |
144 |
4566 |
oxidoreductase activity\, acting on the CH-CH group of donors\, other acceptors |
2.0e-10 |
7 |
7.0 |
99 |
10 |
4566 |
cytochrome P450 activity |
2.0e-10 |
8 |
8.0 |
99 |
15 |
4566 |
microsome |
2.9e-10 |
13 |
13.1 |
99 |
61 |
4566 |
inner membrane |
5.1e-09 |
9 |
9.0 |
99 |
29 |
4566 |
mitochondrial electron transport\, NADH to ubiquinone |
5.5e-09 |
7 |
7.0 |
99 |
14 |
4566 |
mitochondrial inner membrane |
9.3e-09 |
10 |
10.1 |
99 |
41 |
4566 |
ATP synthesis coupled electron transport (sensu Eukarya) |
1.0e-08 |
7 |
7.0 |
99 |
15 |
4566 |
plasmodesma |
1.3e-08 |
15 |
15.1 |
99 |
114 |
4566 |
membrane fraction |
1.4e-08 |
24 |
24.2 |
99 |
304 |
4566 |
fatty acid beta-oxidation |
1.7e-08 |
6 |
6.0 |
99 |
10 |
4566 |
fatty acid oxidation |
1.7e-08 |
6 |
6.0 |
99 |
10 |
4566 |
protein-disulfide reduction |
1.7e-08 |
7 |
7.0 |
99 |
16 |
4566 |
acyl-CoA dehydrogenase activity |
2.5e-08 |
5 |
5.0 |
99 |
6 |
4566 |
carboxylic acid metabolism |
2.7e-08 |
16 |
16.1 |
99 |
138 |
4566 |
NADH dehydrogenase activity |
2.9e-08 |
8 |
8.0 |
99 |
25 |
4566 |
oxidative phosphorylation |
2.9e-08 |
7 |
7.0 |
99 |
17 |
4566 |
organic acid metabolism |
3.0e-08 |
16 |
16.1 |
99 |
139 |
4566 |
NADH dehydrogenase (ubiquinone) activity |
4.1e-08 |
8 |
8.0 |
99 |
26 |
4566 |
hydrogen ion transporter activity |
7.2e-08 |
10 |
10.1 |
99 |
50 |
4566 |
sodium ion transporter activity |
7.2e-08 |
10 |
10.1 |
99 |
50 |
4566 |
cbb3-type cytochrome c oxidase |
7.4e-08 |
6 |
6.0 |
99 |
12 |
4566 |
endoplasmic reticulum |
9.8e-08 |
16 |
16.1 |
99 |
151 |
4566 |
catalytic activity |
1.1e-07 |
62 |
62.6 |
99 |
1677 |
4566 |
cytochrome c oxidase activity |
1.3e-07 |
6 |
6.0 |
99 |
13 |
4566 |
energy reserve metabolism |
1.3e-07 |
6 |
6.0 |
99 |
13 |
4566 |
peroxisome |
1.4e-07 |
8 |
8.0 |
99 |
30 |
4566 |
glycolysis |
1.6e-07 |
7 |
7.0 |
99 |
21 |
4566 |
metal ion transporter activity |
4.4e-07 |
10 |
10.1 |
99 |
60 |
4566 |
oxidoreductase activity\, acting on paired donors\, with incorporation or reduction of molecular oxygen\, reduced flavin or flavoprotein as one donor\, and incorporation of one atom of oxygen |
5.0e-07 |
5 |
5.0 |
99 |
9 |
4566 |
cation transporter activity |
4.0e-06 |
8 |
8.0 |
99 |
45 |
4566 |
glycogen metabolism |
1.3e-05 |
4 |
4.0 |
99 |
8 |
4566 |
oxidoreductase activity\, acting on CH-OH group of donors |
1.4e-05 |
8 |
8.0 |
99 |
53 |
4566 |
oxidoreductase activity\, acting on the CH-OH group of donors\, NAD or NADP as acceptor |
1.4e-05 |
8 |
8.0 |
99 |
53 |
4566 |
mitochondrial electron transport chain |
2.4e-05 |
4 |
4.0 |
99 |
9 |
4566 |
hydro-lyase activity |
2.8e-05 |
6 |
6.0 |
99 |
29 |
4566 |
lyase activity |
3.1e-05 |
9 |
9.0 |
99 |
76 |
4566 |
synaptic junction |
3.1e-05 |
14 |
14.1 |
99 |
183 |
4566 |
regulation of metabolism |
7.9e-05 |
20 |
20.2 |
99 |
365 |
4566 |
carbon-oxygen lyase activity |
8.7e-05 |
6 |
6.0 |
99 |
35 |
4566 |
isocitrate dehydrogenase activity |
9.5e-05 |
3 |
3.0 |
99 |
5 |
4566 |
oxidoreductase activity\, acting on the CH-CH group of donors\, oxygen as acceptor |
9.5e-05 |
3 |
3.0 |
99 |
5 |
4566 |
mitochondrial matrix |
0.0001 |
5 |
5.0 |
99 |
23 |
4566 |